RESEARCH TRIANGLE PARK, N.C.–Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer. “Dave has provided meaningful contributions and leadership since joining Tranzyme said Vipin Garg, PhD, Tranzyme’s President and Chief Executive Officer. I look forward to working with him in his new role as we continue to advance the Company.” Mr. Moore joined Tranzyme in August 2011 from Johnson & Johnson as Vice President, Commercial Operations and his responsibilities were increased in January 2012 to include the oversight of Business Development.

In his new role as Chief Business Officer, Mr. Moore will be responsible for corporate development for the Company, including new discovery collaborations and advancing new opportunities for clinical stage assets, in addition to an increase in general management responsibilities.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, there are a limited number of safe and effective treatment options. By leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company’s website at www.tranzyme.com.